Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.

Conclusion: Decitabine in combination with chemotherapy or molecular therapy has shown efficacious properties in refractory or relapsed AML patients. PMID: 31242832 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31242832?dopt=Abstract

Source: Hematology - June 29, 2019 Category: Hematology Tags: Hematology Source Type: research